Accessible restroom project moving forward at Ashtabula Arts Center
The accessible restroom will include a universal changing table, which is large enough to serve anybody of any size or background.
Ashtabula Arts Center Executive Director Lori Starling said arts center leadership are hoping to have the restroom done by the start of indoor theater show season in the fall.
'It's not just a bathroom,' she said. 'For those individuals that struggle finding places to attend because of their mobility issues, or anything else, it is a big deal, because they actually map out the route of where they can use the bathroom.'
Starling said to her, accessibility means anyone can come to the arts center and enjoy its programs.
'We want this to be an all-inclusive space,' she said.
Accessing an average public restroom is often not simple for someone who has mobility issues, Starling said.
'People that are coming through the area, even if they're traveling somewhere else, can actually look us up on a map, stop here and know that we have that universal changing table,' she said.
A portion of the funding for the construction, $45,000, comes from the state's capital budget.
Ohio State Senator Sandra O'Brien said she has been a supporter of the arts center for a long time.
'My children grew up here in theater,' she said. 'I tell people that the quality of our arts is pretty amazing, for the amount of people we have in the county.'
O'Brien said the art center's program allowed her children to become friends with people of all ages.
'Being in the same play together, they would laugh together,' she said.
O'Brien presented a certificate from the Ohio General Assembly honoring the arts center.
The Ashtabula County Board of Development Disabilities also contributed $20,000 to the project.
Board of DD Community Outreach Specialist Angela Thomas said the board also donated a universal changing table for the project.
Board of DD Director of Early Intervention Amanda Clugh said accessibility means that anyone can have a dignified space where they can use a restroom.
'With this restroom, if you're somebody that needs additional space, you could attend services, and have the space that you need,' she said.
Clugh said accessible restrooms are being implemented at rest areas across Ohio.
'Our county board has a changing table, and that's the vision we hope to see for the future that any restroom would be accessible,' she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Pfizer battles another Paxlovid lawsuit from Enanta
If you don't succeed at first, try again – in separate regions. That's the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent infringement relating to Covid-19 treatment pill Paxlovid (nirmatrelvir/ritonavir). In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma company infringed on a patent describing protease inhibitors invented by its scientists. Enanta has now followed that up with another filing in Europe, making the same accusation. Since being emergency authorised in 2021, anti-viral Paxlovid has generated Pfizer more than $26bn in global revenue. This includes a staggering $18.9bn in 2022 when Covid-19 cases were still prevalent. Despite waning demand for Covid-19 treatments, the pill still brought in $1.2bn in 2024, buoyed by government orders. However, Enanta – known for co-developing hepatitis C virus treatment glecaprevir/pibrentasvir with AbbVie – believes Pfizer designed Paxlovid via unlawful means. The US biotech stated it is 'seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '265 Patent) in the manufacture, use and sale of Pfizer's Covid-19 antiviral, Paxlovid'. In an emailed statement to Pharmaceutical Technology, a Pfizer spokesperson said: 'We are confident in our intellectual property (IP) surrounding Paxlovid and will respond in due course in court.' The lawsuit, filed in the European Union's (EU) Unified Patent Court (UPC), targets Pfizer's commercial activity in the 18 countries of the EU. The company confirmed the '265 patent in question is the European counterpart of US patent number 11,358,953 (the '953 Patent) that is the centre of the US lawsuit. Although it is technically ongoing, Enanta's US lawsuit hit a major roadblock. In December 2024, a federal judge in Massachusetts sided with Pfizer, granting that the '953 patent is invalid. Enanta confirmed at the time it would appeal the decision, adding it 'believes strongly in the merits of our case'. Pfizer reported strong Q2 2025 results this month, bucking a tepid earnings window that gripped the wider pharma industry. Sales for the Paxlovid grew 71% while the Covid-19 vaccine Comirnaty revenue surged 95%. However, the legal challenge posed by Enanta marks the second issue Pfizer has had to firefight this week. The big pharma company reported a Phase III trial failure for a sickle cell disease candidate purchased as part of a $5.4bn takeover of Global Blood Therapeutics in 2022. "Pfizer battles another Paxlovid lawsuit from Enanta" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Untitled Art's non-alcoholic beers are sometimes boring, sometimes magic
I like non-alcoholic beer. Well, I like the *idea* of non-alcoholic beer. Being able to recreate the relaxing ritual of cracking a beer without the concern of a minor hangover or the massive calorie load of a boozy IPA is a wonderful hypothesis. But for too long, non-alcoholic beer all tasted the same -- crisply carbonated but undeniably loaded down with cereal grains that made you feel you were sipping a bowl of Grape-Nuts, not a lager. That tide has turned in recent years. Breweries, grasping for market share when America is drinking less alcohol than it has since prohibition, have turned to the NA sector for new streams of income. That's meant a rising tide of THC drinks and booze-free beers. Untitled Art has been kicking around in my fridge since back when it was 3rd Sign -- makers of a pretty good porter but shuttered due to distribution issues. In the years since they've experimented wildly across the spectrum of beers and NA beverages and eventually got bought out by Asahi. Those beers are often hit-or-miss, but they're never boring. Big, sweet dessert stouts and bold IPAs were standouts across the backdrop of contract brewing that's helped Octopi expand to a staple in package stores across the country. How does that apply to their non-alcoholic beers? Let's see what we've got. Mango dragonfruit sour: A I'm drinking this one the way God intended. After thoroughly exhausting myself inflating a raft at my daughter's pool. An extremely Dad scenario deserves an extremely Dad beer, and an NA fruited sour? That'll do. Cracking the can unleashes a wave of fruity slightly tangy aromas backed by just a little bit of lactic acid. The first sip is dense complex and rewarding. The dragon fruit is tangy; slightly sour but sweet enough to remain balanced. The hint of bile that you get from some of the worst sours out there is nowhere to be found, relieving me of my greatest fear. That bit of lactic acid in the slightly denser texture makes us feel more like a milkshake beer than many milkshake IPAs. What you get is a dense, surprisingly low calorie beer. Well, not a beer but, you know, something close to it. It clocks in at 90 calories, which is about 60 percent of a soda or a regular beer. At that value. You're getting a lot of flavor at a light beer's toll on your gut. That's a solid trade. The downside is it's not quite a hoppy refresher in the way a hop water or a light beer are. It's dense. It's more of a sipper and it's probably not the first thing I should have grabbed after modestly strenuous activity. That said, I am enjoying the hell out of it. All in all, it's not what I expected in a good way. It's not quite a sour and not quite a traditional NA beer. Instead, it is its own thing. And that's great. West Coast IPA: B+ The smell off the top is hoppy, with just enough of a stale malt lingering in the background to remind you this is a non-alcoholic beer. The first sip is sharp and refreshing. The bitterness of those hops is up front, but not overwhelming. You get a little of that malt and a crisp, dry finish that leaves you wanting more. That helps cover that traditional NA taste. It's still there, but it's minimal thanks to that beefy, but not tongue-scorching, hop cover. It's still undeniably a booze-free beer, but it's packing a lot of flavor beyond that. It's satisfying in a way similar beers are not. The downside is it's not as special as the dragonfruit sour. It's great for a non-alcoholic beer, but it's still operating within those parameters while the sour felt like something new entirely. The result is refreshing and capable of fulfilling the ritual of a full strength beer. Juicy IPA: B- Here's an interesting combination. Will the fruit of a juicy IPA be able to cover up the NA scent and taste so familiar with the genre? It worked wonders with the dragonfruit sour and I have some high hopes here. Cracking the can, however, unleashes a wave of non-alcoholic beer smells. There aren't a lot of fruit or hops involved spilling out of the aluminum. It's malt all the way. The first sip is crisper and more refreshing than I expected. It's not especially fruity or hoppy. It feels a little bit more like a lager than a pale ale. However, it's crisp. The carbonation is on point and that NA taste that you'd expect from the smell coming off the top doesn't overpower you. It's still very much a non-alcoholic beer, but it's not as egregious as some of the others in the category. Still, it feels like it's missing the mark as a pale ale. You get a hint of citrus toward the end of each sip, which is nice. But you don't really get any of the hops. There's nothing here to bring you back. It feels more like a Blue Moon or a Shock Top -- more forgettable than a big bold juicy IPA you would get from a local brewery. Italian Style Pils: B I'm a little bit hesitant with this one. Italian beers, at least the big ones you find out here, are fairly minimal when it comes to hops or other flavors that could wash over the signature taste of non-alcoholic brews. They're crisp and sharp and other adjectives that stand in for refreshing-but-not-quite-easy-drinking. This pours with a lovely, lacy head that dies down to a lingering quarter inch after a minute. The smell off the top is grain and just a bit of hops. That grain is half the Grape-Nut cereal malt that dominates NA beers and half something sunnier. There's a certain brightness involved that, if nothing else, does raise it higher than similar booze-less brews. That battle carries on in the first sip. It's undoubtedly an NA beer, but it's also sweet and crisp. That gives way to a pleasant aftertaste that lands in the middle. Malty, effervescent and with juuuuust a little citrus involved to make everything a bit more complex. These powers combine to make it refreshing and poundable. It's a great warm weather beer, though it holds up well enough regardless of climate. Chocolate Dark Brew: A First thing first: this smells incredible. Cracking the can unleashes a wave of rich chocolate like you just unwrapped one of those $6 bars of cacao. It smells like a fresh mug of hot chocolate. A really nice start. The first sip is thinner than expected. The carbonation is crisp, and while this is heavier than a lager it's about the same mouthfeel as, say, a big juicy IPA. You get that chocolate flavor, but also some roasted porter notes as well. You go from sweet up front to malty before a crisp, not-quite-dry-but-close finish. It's great. What's even better is the lack of NA cereal vibes coming from it. This tastes like a full-fledged chocolate porter. Maybe not a heavy, eight percent beer, but a lighter version. If you put this in a lineup of six similar, full ABV beers and asked me to pick out the impostor I might still land on it, but that's no guarantee. This sounds like faint praise, but almost anyone who's had a bunch of NA beers knows that distinct taste and how it stands out from your regular sip. Not this Dark Brew. It's sweet and crisp and a little complex. Untitled Art went for a dessert beer and wound up making something that would be just about perfect for a fireside fall night. Even without the alcohol. Oktoberfest: B Let's finish with my favorite beer style. Marzens, festbiers, anything that's a malt bomb is gonna be an easy win for me. Can Untitled Art balance those toasty, crisp and refreshing flavors with the inherent cereal-ness of a non-alcoholic beer? It pours with a fluffy white head. It smells mostly like the real thing, though a sweet, Grape-Nut tinge settles in toward the end. While the sweetness carries through on your tongue, that NA taste is minimal. The feeling you get here is Munich-adjacent malt. It's a bit thin and definitely too sugary, but it's not a typical non-alcoholic brew. That leaves it in a weird spot, but kind of a logical one. Untitled Art's best NA beers are sweet -- the sour and the chocolate dark. That sweetness again crops up to mitigate the feel you're drinking a beer with less than 0.5 percent alcohol by volume. That doesn't jive with your typical marzen, it does sorta work here. While I miss the crisp finish of those beers, this is unique, interesting and refreshing. On the other hand, I can put down a liter of Lowenbrau without issue. This? This would be much more difficult. Still, it doesn't taste like NA beer. That's a win. Would I drink it instead of a Hamm's? This a pass/fail mechanism where I compare whatever I'm drinking to my baseline cheap beer. That's the standby from the land of sky-blue waters, Hamm's. So the question to answer is: on a typical day, would I drink Untitled Art's non-alcoholic beers over a cold can of Hamm's? The sour and the chocolate dark are good enough to be sipped regardless of alcohol content. The others helpful recreate the ritual of cracking a beer. All in all, it's a solid lineup so, yes. This is part of FTW's Beverage of the Week series. Here, we mostly chronicle and review beers, but happily expand that scope to any beverage that pairs well with sports. Yes, even cookie dough whiskey. This article originally appeared on For The Win: Untitled Art's non-alcoholic beers are sometimes boring, sometimes magic
Yahoo
27 minutes ago
- Yahoo
Human Osteoblasts Market to Reach US$ 87.1 Million by 2033
The market is currently experiencing robust growth, fueled by a post-pandemic surge in orthopedic surgeries and significant investment in regenerative medicine. Innovations in 3D bioprinting and smart scaffolds are creating new therapeutic possibilities for bone repair. Chicago, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global human osteoblasts market was valued at US$ 48.2 million in 2024 and is expected to reach US$ 87.1 million by 2033 at a CAGR of 6.8% during the forecast period 2025–2033. The future potential of the human osteoblasts market lies in the convergence of artificial intelligence with advanced biomanufacturing. AI-powered platforms are now capable of analyzing genomic data from 1000s of individuals to predict osteoblast response to new drug compounds, drastically reducing discovery timelines. This synergy is enabling the creation of patient-specific 3D-bioprinted bone grafts. As of 2025, researchers are successfully embedding patient-derived osteoblasts into custom scaffolds with 95% cell viability post-printing. These constructs are being tested in preclinical models for craniofacial reconstruction and spinal fusion, promising a new era of personalized regenerative medicine. Demand for highly characterized osteoblasts for these applications is projected to soar. Download Sample Pages: Another significant growth frontier of the human osteoblasts market is the application of osteoblast research to counteract microgravity-induced bone loss in astronauts. With 3 new long-duration space missions planned by international agencies before 2028, research into osteoblast function in simulated microgravity is intensifying. Furthermore, the veterinary orthopedics market represents a substantial, untapped opportunity. In 2024, an estimated 1.2 million companion animals in the U.S. alone underwent procedures for fractures or degenerative joint diseases. The development of canine and equine osteoblast cell lines for testing new veterinary implants and cell-based therapies is an emerging field that could create an entirely new vertical within the broader market. Key Findings in Human Osteoblasts Market Market Forecast (2033) US$ 87.1 million CAGR 6.8% Top Drivers Rising prevalence of osteoporosis and degenerative bone diseases globally. Technological advancements in cell-based therapies and tissue engineering. Increasing geriatric population driving demand for orthopedic surgical procedures. Top Trends Shift towards personalized medicine using patient-derived osteoblast cultures. Development of 3D bioprinting for creating patient-specific bone grafts. Growing adoption of minimally invasive bone regeneration surgical techniques. Top Challenges Expensive cell-based therapies and procedures. Stringent and complex regulatory approval pathways for new biologics. Top 12 Key Players Strategically Dominate the Evolving Global Human Osteoblasts Market The competitive environment is both concentrated and highly specialized. Analysis in 2024 consistently identifies 12 key players shaping the industry. These include Sigma-Aldrich, Athersys Inc., Cerapedics Inc., CryoLife, Inc., and Cytori Therapeutics Inc. Other notable companies are USA Stem Cell Inc., Vericel Corporation, Wright Medical Group N.V, Biocomposites, BD, Zimmer Biomet, and PromoCell. In the crucial U.S. orthopedic biomaterials sector, a key application area, 3 major competitors—Medtronic, DePuy Synthes, and Stryker—were noted as dominant forces in 2024. Suppliers offer highly specific product lines to meet diverse research needs. As of 2025, PromoCell provides 4 primary product categories related to osteoblasts, including cells and specialized growth media. Similarly, Innoprot offers 2 distinct types of primary human osteoblasts as of 2024 Human Calvarial and Human Femoral Osteoblasts in the human osteoblasts market. InSCREENex provides 1 specific immortalized human osteoblast cell line, CI-huOB. Product quality and performance are paramount. Lonza guarantees 10 population doublings for its Clonetics™ Normal Human Osteoblasts, ensuring robust expansion for 2024 research. Innoprot's immortalized cells demonstrate a growth potential of over 30+ passages, a significant advantage. Recent Product and Technology Launches Signal Rapid Advancement Within the Market Innovation remains a cornerstone of human osteoblasts market growth, with companies actively launching advanced products. On April 15, 2024, CryoLife, Inc. introduced 1 new osteoblast culture system designed to enhance cell viability. Zimmer Biomet followed suit in February 2024, launching 1 new bioreactor system for osteoblast cultivation with improved scalability. Innovation extends to cell preservation. In 2024, PromoCell released 1 new protein- and animal component-free cryopreservation medium, Cryo-SFM Plus, featuring advanced antioxidant technology. Intellectual property is also a key competitive tool. Bone Solutions Inc. was awarded 5 new patents in fiscal year 2025 for its Mg OSTEOCRETE technology, a bone substitute that stimulates osteoblast activity. Practical usability is crucial for clinical adoption. Bone Solutions' Mg OSTEOCRETE boasts a preparation time of just 30 seconds, a significant handling benefit for 2025 applications. To support adjacent research fields, PromoCell also launched 1 new Cancer Media Toolbox in 2024 to facilitate the establishment of primary cancer cell lines and complex 3D tumor models. Active Clinical Trials for Osteoblast-Related Therapies Underpin Future Market Expansion The clinical development pipeline is a strong indicator of future commercial opportunities. In February 2024, Biocomposites initiated 2 Phase 2 clinical trials for its STIMULAN VG® bone graft substitute. These trials will assess efficacy in treating diabetic foot osteomyelitis and stage 4 pressure ulcers. Osteosarcoma research, a critical area for the human osteoblasts market, is also advancing. In 2024, the Osteosarcoma Institute (OSI) sponsored 1 Phase 2 clinical trial in Spain for OMO-103, a promising MYC inhibitor. A remarkable 25 months was the fast-tracked timeline to launch the OMO-103 trial, showcasing increased efficiency in clinical development. In the United States, a 2024 study was published on 1 FDA/IRB-approved GMP-manufactured stem cell product, PSC-01, for knee osteoarthritis. The study showed that a single treatment provided pain reduction and increased function for 2.5 years. Research methodologies are also being refined. A 2024 clinical trial enrolled 30 patients to analyze the effects of lasers on alveolar bone preservation. A Phase 1 trial protocol published in 2024 detailed a 3+3 dose escalation method for a study using human umbilical cord-derived osteoblasts for femoral head osteonecrosis. Favorable Regulatory Approvals in 2024 Create a Promising Outlook for Therapies The regulatory climate for cell and gene therapies in the human osteoblasts market became increasingly favorable in 2024. The FDA approved 7 new cell and gene therapy products Amtagvi, Aucatzyl, Beqvez, Kebilidi, Ryoncil, Symvess, and Tecelra. The pace of approvals is accelerating, with 3 of these therapies gaining approval in early 2024 alone. On December 19, 2024, the FDA approved 1 mesenchymal stem cell product, Ryoncil from Mesoblast. Another landmark approval was granted on November 13, 2024, for 1 gene therapy for AADC deficiency, Kebilidi from PTC Therapeutics. On November 8, 2024, the FDA approved 1 CD19-directed T-cell immunotherapy, obecabtagene autoleucel (Aucatzyl), from Autolus Inc. The recommended dose for Aucatzyl is 410x10^6 CAR-positive viable T-cells. StemCyte received approval for 1 allogeneic hematopoietic stem cell therapy, Regenecyte, on November 26, 2024. Patent activity, a precursor to commercialization, is also strong. Innovators at the University of Pittsburgh were issued 5 patents in August 2024, while University of Minnesota researchers secured 111 US patents in 2024 for various health science discoveries. Significant Funding and Strategic Grants Accelerate Osteoblast-Focused Research and Development Robust financial investment is fueling the engine of scientific discovery across the global human osteoblasts market. The Osteosarcoma Institute (OSI) awarded $1,100,000 to 3 groundbreaking osteosarcoma research projects during its 2023–2024 grant cycle. One of these grants provided $500,000 in funding to Dr. David Lyden's team for a project focused on metastasis. The impact of such funding is often magnified. Building on an initial OSI grant, Baylor College of Medicine secured $4,500,000 in additional funding in 2024 to advance CAR-T therapy research. International collaborations are also being funded. In October 2024, one US–Israel Binational Science Foundation grant was awarded to a team including University of Vermont Cancer Center members to study osteosarcoma epigenetics. Wherein, government funding remains critical. In August 2024, Medical College of Georgia scientists received a five-year grant of $2,400,000 from the National Institute on Aging to study how stress hormones signal the skeleton. Philanthropic efforts are also significant, with over $4,600,000 raised from more than 1,000 donations in 2024 to support the OSI's vital mission. Diverse and Critical Applications Are Driving Widespread Adoption Across Multiple Fields The utility of human osteoblasts market extends across a wide spectrum of research and clinical applications. The dynamic interplay between 2 key cell types, osteoblasts and osteoclasts, is central to bone health, driving research into osteoporosis. In the laboratory, standardized protocols are essential. Human osteoblasts from PromoCell require approximately 3 weeks to show detectable mineralization in culture. Advanced 3D modeling is becoming a standard research tool. InSCREENex's immortalized human osteoblasts can form 3D "mini-bones" when cultured under specific conditions. Suppliers like PromoCell target 3 key application areas cell expansion, culture initiation, and differentiation. A 2024 study highlighted the use of 1 new 3D model based on human fetal osteoblasts to study osteocyte commitment. The clinical relevance is clear. The classic period for new bone formation after a tooth extraction, a process driven by osteoblasts, is 6-10 weeks. A 2025 study analyzed ion release from 3D printed scaffolds at 3 days, 7 days, and 15 days, key time points for osteoblast interaction. Quality Guarantees and Emerging Technologies Redefine the Global Human Osteoblasts Market The reliability of research outcomes depends on the quality of the underlying cell products. Suppliers in the market provide stringent quality guarantees. PromoCell guarantees >500,000 viable cells per cryovial after thawing. Innoprot similarly ensures >500,000 viable cells in each vial, cryopreserved at passage one, while Lonza guarantees ≥500,000 viable cells per ampule. For immortalized lines, Innoprot provides >1,000,000 viable cells per vial, and InSCREENex includes >0.5 million viable cells per vial. Longevity in culture is also specified. Innoprot guarantees 15 population doublings for its primary osteoblasts post-delivery. PromoCell recommends a split ratio of 1:3 to 1:6 for its primary cells. To support targeted research, PromoCell holds >100 HLA-typed cell donors in stock as of 2024, offering 4-digit high-resolution typing. The InSCREENex cell line was derived from a 63-year-old female donor. Concurrently, emerging technologies are creating new opportunities for the human osteoblasts market. Three key trends noted in the 2024 orthopedic biomaterials market are biodegradable materials, 3D printing, and nanotechnology. A September 2024 paper detailed 1 study using collagen-based 3D printed scaffolds to investigate osteoblast activity. A May 2024 publication described 1 new 3D in-vitro model using human fetal osteoblasts. A 2025 study utilized 2 cell lines to test 3D printed composite samples, using standards prepared from 1,000 mg/L stock solutions and a plating density of 10,000 cells/well for viability tests. Customize the Data Scope to Match Your Objectives: Strategic Alliances and Focused Regional Developments Indicate Strong Global Market Growth Corporate strategies and regional activities in 2024 and 2025 underscore a commitment to global expansion of the human osteoblasts market. On March 10, 2024, 1 major collaboration was announced between Athersys Inc. and Cerapedics Inc. to develop a novel osteoblast-based therapy. Service providers are also expanding. In 2024, Thermo Fisher launched its "Accelerator™ Drug Development" solutions, offering 360-degree support to biotech companies. Licensing agreements are expanding market access for key biologics. Bio-Thera Solutions entered into 1 exclusive licensing agreement on December 24, 2024, for its ustekinumab biosimilar. On the same day, GlycoNex announced 1 licensing agreement for its denosumab biosimilar, a therapy for bone loss. Regional market activities are intensifying. In 2024, 1 pivotal Phase 2 trial for osteosarcoma was opened in Barcelona, Spain. Stryker expanded with 1 new testing facility in India in February 2024. In May 2024, Sanofi announced 1 new partnership with OpenAI to accelerate R&D. The North American market saw the FDA grant 1 US approval to Pfizer's Beqvez on April 25, 2024. Europe showed activity with 1 approval by the UK's MHRA on January 15, 2025. The Asia-Pacific region is also growing, evidenced by 1 approval in Japan on January 7, 2025, for Biocon's ustekinumab. Global Human Osteoblasts Market Major Players: Athelas Bionova Scientific Cell Signaling Technology Corning EMD Millipore Invitrogen Lonza Merck Group NantKwest Promega R and D Systems ReproCELL Sigma-Aldrich Stemcell Technologies Thermo Fisher Scientific Other Prominent Players Key Market Segmentation: By Product Human Cell Culture Osteoblast Cell Lines By Application Traumatic Injuries Road Accidents Regeneration Surgeries Orthopedics Musculoskeletal and Spine Neurology By End user Hospitals Specialty Clinics Ambulatory Surgical Centers By Region North America Europe Asia Pacific Middle East & Africa South America Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
